Ozempic Gastroparesis Attorney: What Documentation Supports a Claim?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

Our Legacy of Evidence-Based Health Information

For decades, the Immunodeficiency Foundation has served as a trusted editorial archive, preserving the scientific and historical records that illuminate the complexities of human health. Our mission has centered on providing clear, evidence-informed context for a broad audience, from general health inquiries to specialized scientific reference. This legacy of accessible, neutral information has long supported individuals seeking to understand the interplay between medical science and real-world outcomes. As our understanding of pharmaceutical interventions deepens, the same rigorous framework now applies to emerging patterns of patient experience. In the context of mass production and widespread drug distribution, the transition from general health awareness to specific exposure concerns becomes critical. The widespread use of glucagon-like peptide-1 receptor agonists, such as Ozempic, has introduced new considerations for individuals who may have experienced adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying—has been reported in association with such exposure. For those pursuing legal claims related to Ozempic-induced gastroparesis, the documentation required mirrors the meticulous standards of our archival tradition. Medical records, prescription histories, and diagnostic imaging form the evidentiary backbone. This shift from general health science to occupational and pharmaceutical exposure underscores the need for precise, verifiable documentation—a principle that has always guided our work.

Understanding Gastroparesis and Its Link to Ozempic

The clinical presentation of gastroparesis involves delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis is typically confirmed through gastric emptying scintigraphy or breath testing. Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes, has been associated with gastrointestinal adverse reactions that may mimic or exacerbate gastroparesis. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying through activation of GLP-1 receptors on vagal afferent neurons and enteric neurons, reducing antral contractility and increasing pyloric tone. This pharmacodynamic effect is intended to improve glycemic control but can lead to clinically significant delayed gastric emptying, particularly in susceptible individuals.

Evidence from Clinical Trials and Post-Market Reports

The FDA Adverse Event Reporting System (FAERS) database lists impaired gastric emptying as a frequently reported adverse event associated with Ozempic, with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). Other frequently reported gastrointestinal events include nausea (8,652 reports), vomiting (5,578 reports), diarrhea (5,274 reports), constipation (3,859 reports), dyspepsia (1,374 reports), and abdominal distension (1,408 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). These reports suggest a plausible link between Ozempic use and gastroparesis, though individual causality requires careful evaluation. For patients pursuing an injury claim related to Ozempic-associated gastroparesis, documentation should include medical records confirming the diagnosis of gastroparesis through objective testing (e.g., gastric emptying scintigraphy) and establishing a temporal relationship between Ozempic initiation and symptom onset. The timeline between exposure and documented harm is critical: gastrointestinal adverse reactions often occur during dose escalation, as noted in clinical trials, but symptoms may persist or worsen with continued use.

Adequacy of Warnings and Legal Considerations

The adequacy of warnings regarding Ozempic and gastroparesis is a key consideration. The prescribing information for Ozempic lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct adverse event. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that discontinuation rates due to these reactions were higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the term "impaired gastric emptying" is not included in the label's adverse reactions section, which may affect the adequacy of warnings for patients and prescribers. Attorney-related considerations for affected patients include the need to gather comprehensive medical records, including prescription history, symptom diaries, and diagnostic test results. Patients should document the date of Ozempic initiation, dose changes, and the onset of gastroparesis symptoms. The FAERS data showing 2,693 reports of impaired gastric emptying (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC) can support the argument that this adverse event is known to the manufacturer. Legal claims may focus on failure to warn, as the label does not specifically mention gastroparesis or impaired gastric emptying as a potential adverse reaction, despite clinical trial data showing gastrointestinal effects and post-market reports. Patients should also consider whether their healthcare provider was adequately informed about the risk of gastroparesis when prescribing Ozempic.

Documentation Checklist for Your Claim

In summary, documentation supporting an Ozempic gastroparesis injury claim includes medical records confirming gastroparesis diagnosis, evidence of a temporal link between Ozempic use and symptom onset, and data from clinical trials and FAERS showing a higher incidence of gastrointestinal adverse reactions and reports of impaired gastric emptying. The adequacy of warnings in the prescribing information is a central issue, as the label does not explicitly address gastroparesis. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate the strength of their claim based on individual circumstances. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166 https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis is typically confirmed through gastric emptying scintigraphy or breath testing.

What documentation is needed for an Ozempic gastroparesis injury claim?

Documentation should include medical records confirming gastroparesis diagnosis through objective testing, evidence of a temporal relationship between Ozempic initiation and symptom onset, prescription history, symptom diaries, and data from clinical trials and FAERS showing a higher incidence of gastrointestinal adverse reactions and reports of impaired gastric emptying.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.